238 related articles for article (PubMed ID: 27469383)
1. Expanding the range of immunopathology in neuromyelitis optica spectrum disorder.
Massey J; Buckland ME; Barnett Y; Sutton I
BMJ Case Rep; 2016 Jul; 2016():. PubMed ID: 27469383
[TBL] [Abstract][Full Text] [Related]
2. [Recent progress in multiple sclerosis research: astrocytopathy in demyelinating diseases].
Kira J
Rinsho Shinkeigaku; 2010 Nov; 50(11):788-93. PubMed ID: 21921443
[TBL] [Abstract][Full Text] [Related]
3. Aquaporin-4 autoantibodies cause asymptomatic aquaporin-4 loss and activate astrocytes in mouse.
Chan KH; Zhang R; Kwan JS; Guo VY; Ho PW; Ho JW; Chu AC
J Neuroimmunol; 2012 Apr; 245(1-2):32-8. PubMed ID: 22394609
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions.
Popescu BF; Guo Y; Jentoft ME; Parisi JE; Lennon VA; Pittock SJ; Weinshenker BG; Wingerchuk DM; Giannini C; Metz I; Brück W; Shuster EA; Carter J; Boyd CD; Clardy SL; Cohen BA; Lucchinetti CF
Neurology; 2015 Jan; 84(2):148-58. PubMed ID: 25503621
[TBL] [Abstract][Full Text] [Related]
5. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.
Roemer SF; Parisi JE; Lennon VA; Benarroch EE; Lassmann H; Bruck W; Mandler RN; Weinshenker BG; Pittock SJ; Wingerchuk DM; Lucchinetti CF
Brain; 2007 May; 130(Pt 5):1194-205. PubMed ID: 17282996
[TBL] [Abstract][Full Text] [Related]
6. Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica.
Saikali P; Cayrol R; Vincent T
Autoimmun Rev; 2009 Dec; 9(2):132-5. PubMed ID: 19389490
[TBL] [Abstract][Full Text] [Related]
7. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury.
Marignier R; Nicolle A; Watrin C; Touret M; Cavagna S; Varrin-Doyer M; Cavillon G; Rogemond V; Confavreux C; Honnorat J; Giraudon P
Brain; 2010 Sep; 133(9):2578-91. PubMed ID: 20688809
[TBL] [Abstract][Full Text] [Related]
8. Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate.
Brück W; Popescu B; Lucchinetti CF; Markovic-Plese S; Gold R; Thal DR; Metz I
Ann Neurol; 2012 Sep; 72(3):385-94. PubMed ID: 23034911
[TBL] [Abstract][Full Text] [Related]
9. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment.
Vincent T; Saikali P; Cayrol R; Roth AD; Bar-Or A; Prat A; Antel JP
J Immunol; 2008 Oct; 181(8):5730-7. PubMed ID: 18832732
[TBL] [Abstract][Full Text] [Related]
10. Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese.
Chan KH; Ramsden DB; Yu YL; Kwok KH; Chu AC; Ho PW; Kwan JS; Lee R; Lim E; Kung MH; Ho SL
Eur J Neurol; 2009 Mar; 16(3):310-6. PubMed ID: 19138340
[TBL] [Abstract][Full Text] [Related]
11. [Neuromyelitis optica: a clinical update].
Chiquete E; Navarro-Bonnet J; Ayala-Armas R; Gutiérrez-Gutiérrez N; Solórzano-Meléndez A; Rodríguez-Tapia D; Gómez-Rincón M; Ruiz-Sandoval JL
Rev Neurol; 2010 Sep; 51(5):289-94. PubMed ID: 20669128
[TBL] [Abstract][Full Text] [Related]
12. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
[TBL] [Abstract][Full Text] [Related]
13. Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica.
Tradtrantip L; Yao X; Su T; Smith AJ; Verkman AS
Acta Neuropathol; 2017 Jul; 134(1):35-44. PubMed ID: 28567523
[TBL] [Abstract][Full Text] [Related]
14. Neuromyelitis optica.
Matiello M; Jacob A; Wingerchuk DM; Weinshenker BG
Curr Opin Neurol; 2007 Jun; 20(3):255-60. PubMed ID: 17495617
[TBL] [Abstract][Full Text] [Related]
15. Glycyrrhizic acid prevents astrocyte death by neuromyelitis optica-specific IgG via inhibition of C1q binding.
Kim JS; Cheon S; Kim SW; Kim B; Kim H; Park KD; Kim SM
Biochem Biophys Res Commun; 2016 Sep; 478(2):553-8. PubMed ID: 27462020
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica.
Hinson SR; Pittock SJ; Lucchinetti CF; Roemer SF; Fryer JP; Kryzer TJ; Lennon VA
Neurology; 2007 Dec; 69(24):2221-31. PubMed ID: 17928579
[TBL] [Abstract][Full Text] [Related]
17. Complexity and heterogeneity in demyelinating disease.
Compston A
Brain; 2007 May; 130(Pt 5):1178-80. PubMed ID: 17472981
[No Abstract] [Full Text] [Related]
18. Effector functions of antiaquaporin-4 autoantibodies in neuromyelitis optica.
Cayrol R; Saikali P; Vincent T
Ann N Y Acad Sci; 2009 Sep; 1173():478-86. PubMed ID: 19758189
[TBL] [Abstract][Full Text] [Related]
19. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2.
Hinson SR; Roemer SF; Lucchinetti CF; Fryer JP; Kryzer TJ; Chamberlain JL; Howe CL; Pittock SJ; Lennon VA
J Exp Med; 2008 Oct; 205(11):2473-81. PubMed ID: 18838545
[TBL] [Abstract][Full Text] [Related]
20. Changes in B and T-cell subsets and NMO-IgG levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica.
de Andrés C; Teijeiro R; Saiz A; Fernández P; Sánchez-Ramón S
Neurologia; 2015 Jun; 30(5):276-82. PubMed ID: 24674779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
